GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (XBUL:LLY) » Definitions » Cyclically Adjusted PB Ratio

Eli Lilly and Co (XBUL:LLY) Cyclically Adjusted PB Ratio : 68.85 (As of Dec. 13, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PB Ratio?

As of today (2024-12-13), Eli Lilly and Co's current share price is лв783.50. Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was лв11.38. Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is 68.85.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PB Ratio or its related term are showing as below:

XBUL:LLY' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.24   Med: 9.73   Max: 77.55
Current: 63.63

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PB Ratio was 77.55. The lowest was 5.24. And the median was 9.73.

XBUL:LLY's Cyclically Adjusted PB Ratio is ranked worse than
99.54% of 656 companies
in the Drug Manufacturers industry
Industry Median: 2.205 vs XBUL:LLY: 63.63

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eli Lilly and Co's adjusted book value per share data for the three months ended in Sep. 2024 was лв29.577. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is лв11.38 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PB Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.17 13.64 22.03 28.80 46.93

Eli Lilly and Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.35 46.93 62.43 73.12 72.05

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PB Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=783.50/11.38
=68.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Eli Lilly and Co's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=29.577/133.0289*133.0289
=29.577

Current CPI (Sep. 2024) = 133.0289.

Eli Lilly and Co Quarterly Data

Book Value per Share CPI Adj_Book
201412 25.870 99.070 34.738
201503 25.127 99.621 33.553
201506 24.734 100.684 32.680
201509 25.674 100.392 34.021
201512 24.640 99.792 32.847
201603 25.414 100.470 33.650
201606 24.783 101.688 32.421
201609 26.393 101.861 34.469
201612 23.781 101.863 31.057
201703 23.767 102.862 30.737
201706 23.937 103.349 30.811
201709 25.275 104.136 32.288
201712 19.696 104.011 25.191
201803 24.847 105.290 31.393
201806 20.109 106.317 25.161
201809 22.897 106.507 28.599
201812 17.378 105.998 21.810
201903 4.775 107.251 5.923
201906 5.380 108.070 6.623
201909 6.585 108.329 8.086
201912 5.088 108.420 6.243
202003 6.013 108.902 7.345
202006 7.998 108.767 9.782
202009 9.432 109.815 11.426
202012 11.023 109.897 13.343
202103 13.438 111.754 15.996
202106 12.591 114.631 14.612
202109 15.156 115.734 17.421
202112 17.598 117.630 19.902
202203 18.345 121.301 20.119
202206 16.808 125.017 17.885
202209 19.808 125.227 21.042
202212 20.948 125.222 22.254
202303 22.033 127.348 23.016
202306 21.783 128.729 22.511
202309 22.091 129.860 22.630
202312 22.385 129.419 23.009
202403 26.595 131.776 26.848
202406 28.151 132.554 28.252
202409 29.577 133.029 29.577

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (XBUL:LLY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eli Lilly and Co Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.